Company intelligence / Profile preview

Nanjing Sanhome Pharmaceutical Co., Ltd.

Nanjing, Jiangsu Province, Chinasanhome.com ↗

Ownership: Private
Employees: ~2500
Development stage: Other

Overview

The company has several approved drugs including Alfosbuvir (NS5B polymerase inhibitor) for Hepatitis C approved in China on May 12, 2023, and Levornidazole (DNA inhibitor) for Bacterial Infections approved in China on August 14, 2009. They also have pipeline products in Phase 1 and 2 clinical trials.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule drugsBiological productsBispecific antibodiesMonoclonal antibodiesMolecular glue
Industry: Biotech

Drug pipeline

33 assets

levornidazole

32 more assets in the full pipeline.

Beyond the preview

Go deeper on Nanjing Sanhome Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Sanhome Pharmaceutical Co., Ltd..